LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) is expected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect LENZ Therapeutics to post earnings of ($0.41) per share for the quarter.
LENZ Therapeutics Price Performance
Shares of NASDAQ LENZ opened at $23.49 on Monday. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93. The firm has a fifty day moving average of $26.54 and a 200-day moving average of $27.01.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $35.40.
About LENZ Therapeutics
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
- Five stocks we like better than LENZ Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- P/E Ratio Calculation: How to Assess Stocks
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- Utilities Stocks Explained – How and Why to Invest in Utilities
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
